AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

ACTINOGEN MEDICAL LTD

0.044

+0.0024.76%

Volume:680.23K

Turnover:29.24K

Market Cap:163.55M

PE:-7.33

High:0.044

Open:0.043

Low:0.042

Close:0.042

52wk High:0.072

52wk Low:0.026

Shares:3.72B

Float Shares:2.61B

Volume Ratio:0.88

T/O Rate:0.03%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.006

EPS(LYR):-0.005

ROE:-77.46%

ROA:-34.56%

PB:7.65

PE(LYR):-8.90

Loading ...

Overview Company News Filings

Actinogen Medical (ASX:ACW) Shares Face Funding Pressure As Losses Deepen

Simply Wall St.

Actinogen Medical Ltd - FY Loss from Ordinary Activities After Tax Attributable A$15.4 Mln

THOMSON REUTERS

Actinogen Medical Ltd - no Dividends Declared in Current or Prior Year

THOMSON REUTERS

Actinogen Medical Advances Oral Enzyme Inhibitor for Potential Alzheimer's Disease Treatment

MT Newswires Live

Actinogen Says Results from Phase Two Trial of Therapy Candidate in Patients with Major Depressive Disorder, Cognitive Impairment Published

MT Newswires Live

Actinogen Medical Ltd-acw Senior Management Presentation at Aaic & Internationally

THOMSON REUTERS

Actinogen Medical Receives Independent DMC Positive Recommendation for Phase 2b/3 Alzheimer's Disease Trial, Shares Jump 10%

MT Newswires Live

Actinogen says EMA backs plan for one additional Phase 3 Xanamem Alzheimer’s trial

Actinogen Receives Positive Ema Scientific Advice Aligned With Prior FDA Guidance for Its Alzheimer’s Disease Program

THOMSON REUTERS

Actinogen Medical - Ema Agrees on Design of Additional Pivotal Phase 3 Trial for Xanamem

THOMSON REUTERS

Actinogen Medical - Co and Ema Agree on Pathway to EU Marketing Approval for Alzheimer's

THOMSON REUTERS

Actinogen Medical Reaches Common Understanding With European Regulator on Pathway to Marketing Approval for Alzheimers' Disease Program

MT Newswires Live

Actinogen Medical Ltd-Acw CEO Options Exercise and Expiry Reminder

THOMSON REUTERS

Actinogen Medical Launches Buy-Back Under New Employee Share Scheme; Shares Fall 3%

MT Newswires Live

Actinogen Medical: in Current Quarter, Co Plans to Meet With Ema to Discuss Opportunities to Streamline Pathway to Xanamem Approval in European Union

THOMSON REUTERS

Actinogen Commences Open-Label Phase of Xanamia Alzheimer’s Trial and Provides Business Update

THOMSON REUTERS

Actinogen Medical Begins Open-Label Extension Phase of Alzheimer's Disease Trial

MT Newswires Live

Actinogen Medical Ltd-CEO Loan-Funded Long-Term Incentive Shares Amendment

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg.tigeractivity.com/stock/ACW.AU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ACW.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"ACW.AU\",,,,,undefined,":{"symbol":"ACW.AU","market":"AU","secType":"STK","nameCN":"ACTINOGEN MEDICAL LTD","latestPrice":0.044,"timestamp":1787897520000,"preClose":0.042,"halted":0,"volume":680231,"delay":0,"changeRate":0.04761904761904749,"nameEN":"ACTINOGEN MEDICAL LTD","floatShares":2607880613,"shares":3717091613,"eps":-0.006,"marketStatus":"Not Yet Opened","change":0.002,"latestTime":"08-28 16:12:00 AEST","open":0.043,"high":0.044,"low":0.042,"amount":29241,"amplitude":0.047619,"askPrice":0.044,"askSize":534398,"bidPrice":0.043,"bidSize":33019,"shortable":3,"etf":0,"ttmEps":-0.006,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1788134400000},"marketStatusCode":0,"adr":0,"exchange":"ASX","adjPreClose":0.042,"openAndCloseTimeList":[[1787875200000,1787896800000]],"volumeRatio":0.8796399148611879,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"ACW.AU","preClose":0.042,"auctionPrice":0.044,"auctionVolume":315,"auction":3,"marketStatus":"盘后竞价","timestamp":1787897386703}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"ACW.AU\",,,,,undefined,":{"symbol":"ACW.AU","floatShares":2607880613,"roa":"-34.56%","roe":"-77.46%","lyrEps":-0.004944,"volumeRatio":0.8796399148611879,"shares":3717091613,"dividePrice":0,"high":0.044,"amplitude":0.047619,"preClose":0.042,"low":0.042,"week52Low":0.026,"pbRate":"7.65","psRate":"12.41","week52High":0.072,"institutionHeld":0,"latestPrice":0.044,"committee":-0.883616,"eps":-0.006,"divideRate":0,"volume":680231,"delay":0,"ttmEps":-0.006,"open":0.043,"prevYearClose":0.061,"prevWeekClose":0.044,"prevMonthClose":0.041,"prevQuarterClose":0.031,"fiveDayClose":0.046,"twentyDayClose":0.041,"sixtyDayClose":0.037,"dividendGrowthYears":0,"fiveYearAvgDividendRate":0},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ACW.AU\",params:#limit:5,,,undefined,":[{"market":"AU","date":"2020-10-19","symbol":"ACW.AU","defaultRemindTime":1603062000000,"type":"split","dateTimestamp":1603026000000,"forFactor":98,"toFactor":100,"ratio":0.98}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ACW.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ACW.AU\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2663701921","title":"Actinogen Medical (ASX:ACW) Shares Face Funding Pressure As Losses Deepen","url":"https://stock-news.laohu8.com/highlight/detail?id=2663701921","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663701921?lang=en_us&edition=fundamental","pubTime":"2026-08-29 04:28","pubTimestamp":1787948898,"startTime":"0","endTime":"0","summary":"Actinogen Medical entered this earnings season as a high risk biotech stock with a thin cash cushion and an unprofitable track record. The share price now trades at A$0.044 after a weak 7 day run and a stronger 3 month climb. The headline from this FY 2026 release is the pressure on the balance sheet. Management reported a loss of A$15.4 million over the trailing 12 months with no clear profitability in view and less than one year of cash runway.\nConcerned by Actinogen Medical's cash runway...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-acw/actinogen-medical-shares/news/actinogen-medical-asxacw-shares-face-funding-pressure-as-los","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-acw/actinogen-medical-shares/news/actinogen-medical-asxacw-shares-face-funding-pressure-as-los","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7067","BK7508","ACW.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662773768","title":"Actinogen Medical Ltd - FY Loss from Ordinary Activities After Tax Attributable A$15.4 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2662773768","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662773768?lang=en_us&edition=fundamental","pubTime":"2026-08-27 14:29","pubTimestamp":1787812170,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nFWN44O0EI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","BK7508","ACW.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662067773","title":"Actinogen Medical Ltd - no Dividends Declared in Current or Prior Year","url":"https://stock-news.laohu8.com/highlight/detail?id=2662067773","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662067773?lang=en_us&edition=fundamental","pubTime":"2026-08-27 14:29","pubTimestamp":1787812170,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nFWN44O0EI:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ACW.AU","BK7508","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657457083","title":"Actinogen Medical Advances Oral Enzyme Inhibitor for Potential Alzheimer's Disease Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2657457083","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657457083?lang=en_us&edition=fundamental","pubTime":"2026-08-06 08:34","pubTimestamp":1785976497,"startTime":"0","endTime":"0","summary":"Actinogen Medical  presented Xanamem, an oral enzyme inhibitor that lowers brain cortisol levels by blocking the 11β-HSD1 enzyme, at the Bioshares Biotech Summit in New Zealand, according to a Thursday filing with the Australian bourse.The company is advancing Xanamem for the potential treatment of Alzheimer's disease by blocking excess stress hormone cortisol production in brain cells, the filing said.The company anticipates top-line results from the fully enrolled phase 2b/3 XanaMIA pivotal trial in November, following independent Data Monitoring Committee recommendation in January that the trial continue unchanged, per the filing.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","ACW.AU","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652261925","title":"Actinogen Says Results from Phase Two Trial of Therapy Candidate in Patients with Major Depressive Disorder, Cognitive Impairment Published","url":"https://stock-news.laohu8.com/highlight/detail?id=2652261925","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652261925?lang=en_us&edition=fundamental","pubTime":"2026-07-20 11:43","pubTimestamp":1784519026,"startTime":"0","endTime":"0","summary":"Actinogen Medical  said results from a proof-of-concept phase two randomized, double-blind, placebo-controlled trial of its therapy candidate, emestedastat or Xanamem, in patients with major depressive disorder  and cognitive impairment  were published as a peer-reviewed article in the British Journal of Psychiatry, according to a Monday Australian bourse filing.The study enrolled 165 participants with clinically significant residual MDD and measurable CI. The trial showed that Xanamem was safe and well-tolerated.The antidepressant benefit compared with placebo was maximal at week 10 of the trial, with 2.7 points on the Montgomery-Asberg Depression Rating scale, during the blinded follow-up phase. A similar benefit was seen in key subgroups, including the 46% of patients who were on background selective serotonin reuptake inhibitor medication with 4.2 points on the Montgomery-Asberg Depression Rating scale.Further Xanamem trials in MDD will depend on future funding and partnership arra","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","IE00BSNM7G36.USD","LU1261432733.SGD","IE0002270589.USD","LU0289739699.SGD","LU0868494617.USD","LU1059921491.USD","ACW.AU","BK4196","IE00B19Z3581.USD","IE00B19Z3B42.SGD","BK4585","CI","LU0058720904.USD","BK7508","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649536719","title":"Actinogen Medical Ltd-acw Senior Management Presentation at Aaic & Internationally","url":"https://stock-news.laohu8.com/highlight/detail?id=2649536719","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649536719?lang=en_us&edition=fundamental","pubTime":"2026-07-08 06:41","pubTimestamp":1783464065,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260707:nTUE6MQF0M:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","ACW.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644738957","title":"Actinogen Medical Receives Independent DMC Positive Recommendation for Phase 2b/3 Alzheimer's Disease Trial, Shares Jump 10%","url":"https://stock-news.laohu8.com/highlight/detail?id=2644738957","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644738957?lang=en_us&edition=fundamental","pubTime":"2026-06-18 08:54","pubTimestamp":1781744044,"startTime":"0","endTime":"0","summary":"Actinogen Medical  received a positive recommendation from the XanaMIA phase 2b/3 Alzheimer's disease trial's independent data monitoring committee  to continue the trial without amendment, according to a Thursday Australian bourse filing.The committee comprises independent clinical and statistical experts who are not connected to the day-to-day conduct or analysis of the trial.The primary endpoint of the trial is the internationally recognized Clinical Dementia Rating scale-Sum of Boxes. Oral Xanamem 10 milligrams daily doses continue to demonstrate a promising safety profile in patients with mild to moderate Alzheimer's disease treated for up to 36 weeks in the trial, it added.Its shares jumped 10% in recent trading on Thursday.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7045","ACW.AU","BK7049","BK7067","BK7508","DMC.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638239698","title":"Actinogen says EMA backs plan for one additional Phase 3 Xanamem Alzheimer’s trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2638239698","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638239698?lang=en_us&edition=fundamental","pubTime":"2026-05-28 20:06","pubTimestamp":1779970010,"startTime":"0","endTime":"0","summary":"Actinogen secured positive EMA scientific advice that maps a pathway to EU approval for Alzheimer’s drug candidate Xanamem.EMA guidance supports one additional phase 3 trial using a single 10 mg dose versus placebo, following the ongoing XanaMIA pivotal study.Topline XanaMIA results have not been presented yet; they are expected in November from a 247-patient trial in the US and Australia.The advice aligns with prior FDA feedback, strengthening the company’s basis for partner talks and multi-region commercialization planning.A second pivotal trial is slated to start mid-next year, with longer-term data to be gathered in an open-label extension.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260528:nNDL3FrPKb:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210149790.SGD","BK7508","SG9999014005.SGD","SG9999014013.SGD","NDAQ","IE00BGHQF748.EUR","LU0314104364.USD","IE00BN0W2T93.GBP","BK7067","LU2210150020.SGD","IE00BN0W2V16.EUR","LU2095319765.USD","BK4585","IE00BN0W2W23.USD","BK4588","SG9999014021.USD","IE00B64PRP62.GBP","IE00BKPKM429.USD","BK4112","IE00B3QW5Z07.USD","SG9999014039.USD","ACW.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638986716","title":"Actinogen Receives Positive Ema Scientific Advice Aligned With Prior FDA Guidance for Its Alzheimer’s Disease Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2638986716","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638986716?lang=en_us&edition=fundamental","pubTime":"2026-05-28 20:00","pubTimestamp":1779969607,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260528:nTUA1YCYZJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","BK7067","ACW.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638869869","title":"Actinogen Medical - Ema Agrees on Design of Additional Pivotal Phase 3 Trial for Xanamem","url":"https://stock-news.laohu8.com/highlight/detail?id=2638869869","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638869869?lang=en_us&edition=fundamental","pubTime":"2026-05-28 20:00","pubTimestamp":1779969607,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260528:nTUA1YCYZJ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","ACW.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638640698","title":"Actinogen Medical - Co and Ema Agree on Pathway to EU Marketing Approval for Alzheimer's","url":"https://stock-news.laohu8.com/highlight/detail?id=2638640698","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638640698?lang=en_us&edition=fundamental","pubTime":"2026-05-28 20:00","pubTimestamp":1779969607,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260528:nTUA1YCYZJ:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","BK7508","ACW.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638653254","title":"Actinogen Medical Reaches Common Understanding With European Regulator on Pathway to Marketing Approval for Alzheimers' Disease Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2638653254","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638653254?lang=en_us&edition=fundamental","pubTime":"2026-05-28 09:53","pubTimestamp":1779933233,"startTime":"0","endTime":"0","summary":"Actinogen Medical  reached a common understanding of the pathway to marketing approval for its Alzheimer's disease program in its scheduled scientific advice meeting with the European Medicines Agency , according to a Thursday Australian bourse filing.The understanding includes the specification of regulatory starting materials for the commercial manufacturing of Xanamem  drug substance, design considerations for an additional pivotal clinical trial, as well as the limited number of ancillary clinical pharmacology trials and nonclinical studies required.The understandings also include ensuring the proposed makeup of the planned safety database is consistent with EMA and US Food and Drug Administration  guidelines.The firm said the understandings align closely with the guidance received at an earlier meeting with the US FDA's Neurology-I division.Actinogen Medical's shares rose nearly 3% in recent trading on Thursday.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","ACW.AU","EPV","BK7129","BK7508","BK4081","EMA.AU","EMA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635267221","title":"Actinogen Medical Ltd-Acw CEO Options Exercise and Expiry Reminder","url":"https://stock-news.laohu8.com/highlight/detail?id=2635267221","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635267221?lang=en_us&edition=fundamental","pubTime":"2026-05-13 08:16","pubTimestamp":1778631376,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260513:nTUE3JD75X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","ACW.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624159521","title":"Actinogen Medical Launches Buy-Back Under New Employee Share Scheme; Shares Fall 3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2624159521","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624159521?lang=en_us&edition=fundamental","pubTime":"2026-04-02 11:00","pubTimestamp":1775098824,"startTime":"0","endTime":"0","summary":"Actinogen Medical  has launched a buy-back of its ordinary fully paid shares under a new employee share scheme, according to a Thursday Australian bourse filing.The company proposed to buy back a maximum of around 2.8 million of its ordinary shares, per the filing.The buy-back is expected to commence on April 28, the filing added.The company's shares fell 3% in recent Thursday trade.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ACW.AU","BK7508","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624515941","title":"Actinogen Medical: in Current Quarter, Co Plans to Meet With Ema to Discuss Opportunities to Streamline Pathway to Xanamem Approval in European Union","url":"https://stock-news.laohu8.com/highlight/detail?id=2624515941","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624515941?lang=en_us&edition=fundamental","pubTime":"2026-04-01 20:30","pubTimestamp":1775046600,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260401:nTUA53THZ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","ACW.AU","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624515556","title":"Actinogen Commences Open-Label Phase of Xanamia Alzheimer’s Trial and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2624515556","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624515556?lang=en_us&edition=fundamental","pubTime":"2026-04-01 20:30","pubTimestamp":1775046600,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260401:nTUA53THZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","ACW.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624551094","title":"Actinogen Medical Begins Open-Label Extension Phase of Alzheimer's Disease Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2624551094","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624551094?lang=en_us&edition=fundamental","pubTime":"2026-04-01 07:34","pubTimestamp":1775000050,"startTime":"0","endTime":"0","summary":"Actinogen Medical  began the open-label extension phase of the XanaMIA phase 2b/3 Alzheimer's disease trial with the treatment of the first trial participant, according to a Wednesday Australian bourse filing.The open-label phase consists of up to 25 months of treatment, during which all participants will receive 10 milligrams of the active Xanamem drug candidate once daily, with no placebo control group.The phase will generate longer-term safety and observational data on efficacy endpoints, including the Clinical Dementia Rating Scale Sum of Boxes, cognition, and activities of daily living.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ACW.AU","BK7067","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619857154","title":"Actinogen Medical Ltd-CEO Loan-Funded Long-Term Incentive Shares Amendment","url":"https://stock-news.laohu8.com/highlight/detail?id=2619857154","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619857154?lang=en_us&edition=fundamental","pubTime":"2026-03-16 06:04","pubTimestamp":1773612284,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260315:nTUE5QQMV7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","ACW.AU","BK7508"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":18,"code":"91000000","status":"200"}]}}